Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentActive18 and overNCINCI-2009-00587
CDR0000546714, GOG-0213, U10CA180868, U10CA027469, NCT00565851

Trial Description

Summary

This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer that has come back. Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective when given with or without bevacizumab after surgery in treating patients with ovarian epithelial cancer, primary peritoneal cavity cancer, or fallopian tube cancer.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases the duration of overall survival in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

II. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

SECONDARY OBJECTIVES:

I. To determine if the addition of bevacizumab to the second-line and maintenance phase of treatment increases the duration of progression-free survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer.

II. To prospectively determine the incidence of carboplatin and paclitaxel hypersensitivity in these patients undergoing retreatment with both agents as first recurrence therapy.

III. To determine if surgical secondary cytoreduction in addition to adjuvant chemotherapy increases quality of life (QOL) in patients with recurrent platinum-sensitive ovarian epithelial cancer, peritoneal primary or fallopian tube cancer, as measured by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) trial outcome index and Rand Short Form (SF)-36 physical functioning scale.

IV. To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases QOL relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum-sensitive ovarian epithelial, peritoneal primary or fallopian tube cancer.

TERTIARY OBJECTIVES:

I. To define molecular and biochemical profiles associated with the duration of progression-free survival in platinum-sensitive recurrent ovarian, peritoneal primary or fallopian tube carcinoma treated with combination chemotherapy with or without bevacizumab followed with or without maintenance bevacizumab therapy in the presence or absence of secondary surgical cytoreduction.

II. To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy.

III. To bank deoxyribonucleic acid (DNA) from whole blood for research and evaluate the association between single nucleotide polymorphisms (SNPs) and measures of clinical outcome including overall survival, progression-free survival and adverse events.

OUTLINE: Patients are assigned to 1 of 4 treatment groups. Patients who are not candidates for surgical cytoreduction (i.e., those for whom complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking) are eligible to receive chemotherapy after randomization.

Patients who are eligible for surgery undergo abdominal exploration with cytoreduction. Patients are then randomized to 1 of 4 treatment arms.

ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours or docetaxel IV over 1 hour and carboplatin IV over 60 minutes on day 1.

ARM II: Patients receive chemotherapy as in Arm I and bevacizumab IV over 30-90 minutes on day 1.

ARM III: Patients receive gemcitabine hydrochloride IV over 60 minutes on days 1 and 8 and carboplatin as in Arm I.

ARM IV: Patients receive gemcitabine hydrochloride IV as in Arm III, bevacizumab IV and carboplatin IV as in Arm II.

In all arms, courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients with measurable disease achieving a clinical response (CR) receive 6-8 courses of therapy. Patients with stable disease or partial regression receive a maximum of 8 courses.

Patients without measurable lesions as determined by a computed tomography (CT) scan prior to initiating study treatment continue therapy for 6 courses or, if cancer antigen (CA)-125 normalizes, for 2 courses beyond CA-125 normalization, whichever is greater. Patients in Arm II then receive a maintenance regimen comprising bevacizumab IV over 30-90 minutes. Treatment with bevacizumab alone repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically for 10 years.

Eligibility Criteria

Inclusion Criteria:

  • Patients enrolled after August 28, 2011 must be candidates for cytoreductive surgery and consent to have their surgical treatment determined by randomization
  • Patients must have histologic diagnosis of epithelial ovarian carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrent
  • Patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, transitional cell carcinoma, malignant Brenner's tumor, or adenocarcinoma not otherwise specified (N.O.S.)
  • Patients must have had a complete response to front-line platinum-taxane therapy (at least three cycles)
  • A complete response to front-line chemotherapy must include: negative physical exam, negative pelvic exam and normalization of CA125, if elevated at baseline; although not required, any radiographic assessment of disease status (e.g. CT, magnetic resonance imaging [MRI], positron emission tomography [PET]/CT, etc) obtained following the completion of primary therapy should be considered negative for disease
  • All patients must have also had a treatment-free interval without clinical evidence of progressive disease of at least 6 months from completion of front-line chemotherapy (both platinum and taxane); front-line therapy may have included a biologic agent (i.e. bevacizumab)
  • Front-line treatment may include maintenance therapy following complete clinical or pathological response; however, maintenance cytotoxic chemotherapy must be discontinued for a minimum of 6 months prior to documentation of recurrent disease; patients receiving maintenance biological therapy or hormonal therapy are ELIGIBLE provided their recurrence is documented more than 6 months from primary cytotoxic chemotherapy completion (includes maintenance chemotherapy) AND a minimum 4 weeks has elapsed since their last infusion of biological therapy
  • Patients must have clinically evident recurrent disease for the purpose of this study
  • Measurable disease (Response Evaluation Criteria in Solid Tumors [RECIST]) is defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded); each lesion must be more than or equal to 20 mm when measured by conventional techniques, MRI or CT, or more than or equal to 10 mm when measured by spiral CT
  • Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3, equivalent to Common Toxicity Criteria for Adverse Events version (v)3.0 (CTCAE) grade 1
  • Platelets greater than or equal to 100,000/mm^3 (CTCAE grade 0-1)
  • Creatinine (non-isotope dilution mass spectrometry [IDMS]) =< 1.5 x institutional upper limit normal (ULN), CTCAE grade 1
  • Total bilirubin =< 1.5 ULN (CTCAE grade 1)
  • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) =< 2.5 times the upper limit of normal in the absence of liver metastasis; SGOT/AST < 5.0 times ULN in the presence of liver metastasis
  • Alkaline phosphatase =< 2.5 times the upper limit of normal in the absence of liver metastasis; alkaline phosphatase < 5.0 times ULN in the presence of liver metastasis
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
  • This eligibility criterion does not apply to patients enrolled after August 28, 2011; patients who are not candidates for surgical cytoreduction are eligible for the chemotherapy randomization; patients are not considered candidates for surgical cytoreduction if complete cytoreduction in the estimation of the investigator is impossible or a medical infirmity precludes exploration and debulking
  • Patients must have met the pre-entry requirements specified
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information
  • Patients must have a Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2

Exclusion Criteria:

  • Patients who have received more than one previous regimen of chemotherapy (maintenance is not considered a second regimen)
  • Patients receiving concurrent immunotherapy, or radiotherapy
  • Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
  • Patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
  • Patients with a prior histologic diagnosis of borderline, low malignant potential (grade 0) epithelial carcinoma that was surgically resected and who subsequently developed an unrelated, new invasive epithelial ovarian or peritoneal primary cancer are eligible provided that they meet the criteria listed
  • Patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation
  • Patients who have received prior chemotherapy for any abdominal or pelvic tumor (other than ovarian, fallopian tube, and primary peritoneal) are excluded
  • Patients with synchronous primary endometrial cancer, or a past history of primary endometrial cancer, are excluded, unless all of the following conditions are met: stage not greater than I-B; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell or other International Federation of Gynecology and Obstetrics (FIGO) grade 3 lesions
  • Patients with uncontrolled infection
  • Patients with concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to extreme risk or decreased life expectancy
  • Patients with >= grade 2 peripheral neuropathy
  • Patients with a history of allergic reactions to carboplatin and/or paclitaxel or chemically similar compounds; patients with allergic (hypersensitivity) reactions to these chemotherapeutic agents are NOT excluded IF they were successfully retreated following a desensitization program or protocol
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
  • Patients of childbearing potential, not practicing adequate contraception, patients who are pregnant or patients who are nursing are not eligible for this trial; bevacizumab should not be administered to nursing women
  • Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol therapy
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with active bleeding or pathologic conditions that carry high risk of bleeding such as a known bleeding disorder, coagulopathy, or tumor involving major vessels
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with a history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases or a history of stroke within 5 years of the first date of treatment on this study
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients with clinically significant cardiovascular disease; this includes:
  • Patients with significant cardiac conduction abnormalities, i.e. PR interval > 0.24 seconds (sec) or 2nd or 3rd degree atrioventricular (AV) block
  • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
  • Myocardial infarction, cardiac arrhythmia or unstable angina < 6 months prior to registration
  • New York Heart Association (NYHA) grade II or greater congestive heart failure
  • Serious cardiac arrhythmia requiring medication
  • Grade II or greater peripheral vascular disease (exception: episodes of ischemia < 24 hours [hrs] in duration, that are managed non-surgically and without permanent deficit)
  • History of cerebrovascular attack (CVA) within six months
  • This criterion applies only to the patients enrolled before August 29, 2011 and those enrolled after this date electing to receive bevacizumab; patients who have had a major surgical procedure, open biopsy, dental extractions or other dental surgery/procedure that results in an open wound, or significant traumatic injury within 28 days prior to the first date of treatment on this study, or anticipation of need for major surgical procedure during the course of the study; patients with placement of vascular access device or core biopsy within 7 days prior to the first date of treatment on this study
  • Patients undergoing pre-treatment secondary cytoreduction will undergo therapy with bevacizumab on cycle #2
  • Patients undergoing pre-treatment surgery for purposes other than cytoreduction may also participate provided they meet eligibility; patients randomized to arms containing bevacizumab must wait a minimum of 28 days since that procedure to begin protocol treatment; patients who undergo an uncomplicated port placement must wait a minimum of 7 days to begin protocol treatment

Trial Contact Information

Trial Lead Organizations/Sponsors

National Cancer Institute

    Robert Coleman, Principal Investigator

    Trial Sites

    U.S.A.

    Alaska
    Anchorage

    Alaska Breast Care and Surgery LLC

    Alison K Conlin
    Ph: 503-215-6412

    Alaska Women's Cancer Care

    Alison K Conlin
    Ph: 503-215-6412

    Anchorage Oncology Centre

    Alison K Conlin
    Ph: 503-215-6412

    Katmai Oncology Group

    Alison K Conlin
    Ph: 503-215-6412

    Providence Cancer Center

    Alison K Conlin
    Ph: 503-215-6412

    California
    Auburn

    Auburn Radiation Oncology

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Sutter Auburn Faith Hospital

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Berkeley

    Alta Bates Summit Comprehensive Cancer Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Burlingame

    Peninsula Medical Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Cameron Park

    Radiation Oncology Centers - Cameron Park

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Davis

    Sutter Davis Hospital

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    La Jolla

    Rebecca and John Moores UCSD Cancer Center

    Michael T. McHale
    Ph: 858-822-5354
    Email: cancercto@ucsd.edu

    Long Beach

    Todd Cancer Institute at Long Beach Memorial Medical Center

    Robert E Bristow
    Ph: 562-933-0900

    Los Angeles

    Jonsson Comprehensive Cancer Center at UCLA

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Kaiser Permanente Medical Center - Los Angeles

    Scott E. Lentz
    Ph: 626-564-3455

    Scott E. Lentz
    Ph: 626-564-3455

    Modesto

    Memorial Medical Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Mountain View

    Palo Alto Medical Foundation

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Orange

    Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center

    Krishnansu S Tewari
    Ph: 714-456-6191
    Email: awallick@uci.edu

    Palo Alto

    Palo Alto Medical Foundation - Palo Alto

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Stanford Cancer Center

    Jonathan S. Berek
    Ph: 650-498-7061
    Email: clinicaltrials@med.stanford.edu

    Roseville

    Radiation Oncology Center - Roseville

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Sutter Cancer Center at Roseville Medical Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Sacramento

    Sutter Cancer Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    San Francisco

    California Pacific Medical Center - California Campus

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    UCSF Helen Diller Family Comprehensive Cancer Center

    Lee-may Chen
    Ph: 877-827-3222

    Santa Cruz

    Palo Alto Medical Foundation-Santa Cruz

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Santa Rosa

    Sutter Pacific Medical Foundation

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Sunnyvale

    Palo Atlo Medical Foundation-Sunnyvale

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Vacaville

    Solano Radiation Oncology Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Vallejo

    Sutter Solano Medical Center

    John K Chan
    Ph: 415-209-2686
    Email: bernicl@sutterhealth.org

    Colorado
    Aurora

    Medical Center of Aurora - South Campus

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers - Aurora

    Keren Sturtz
    Ph: 888-785-6789

    University of Colorado Cancer Center at UC Health Sciences Center

    Saketh R Guntupalli
    Ph: 720-848-0650

    Boulder

    Boulder Community Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers-Boulder

    Keren Sturtz
    Ph: 888-785-6789

    Colorado Springs

    Penrose Cancer Center at Penrose Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers at the Pavilion

    Keren Sturtz
    Ph: 888-785-6789

    Denver

    CCOP - Colorado Cancer Research Program

    Keren Sturtz
    Ph: 888-785-6789

    Colorado Blood Cancer Institute

    Keren Sturtz
    Ph: 888-785-6789

    Porter Adventist Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Presbyterian - St. Luke's Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers - Denver Midtown

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers-Rose

    Keren Sturtz
    Ph: 888-785-6789

    Rose Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    St. Joseph Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Durango

    Mercy Medical Center

    Cynthia K. Cathcart
    Ph: 888-785-6789

    Southwest Oncology, PC

    Keren Sturtz
    Ph: 888-785-6789

    Englewood

    Comprehensive Cancer Care and Research Institute of Colorado LLC

    Keren Sturtz
    Ph: 888-785-6789

    Swedish Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Golden

    Mountain Blue Cancer Care Center

    Keren Sturtz
    Ph: 888-785-6789

    Greeley

    North Colorado Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Greenwood Village

    Breast Cancer Care Consultants

    Keren Sturtz
    Ph: 888-785-6789

    Lakewood

    Rocky Mountain Cancer Centers-Lakewood

    Keren Sturtz
    Ph: 888-785-6789

    St. Anthony Central Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Littleton

    Littleton Adventist Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers - Littleton

    Keren Sturtz
    Ph: 888-785-6789

    Lone Tree

    Rocky Mountain Cancer Centers - Lone Tree

    Keren Sturtz
    Ph: 888-785-6789

    Sky Ridge Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Longmont

    Hope Cancer Care Center at Longmont United Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers - Longmont

    Keren Sturtz
    Ph: 888-785-6789

    Loveland

    McKee Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Parker

    Parker Adventist Hospital

    Keren Sturtz
    Ph: 888-785-6789

    Rocky Mountain Cancer Centers - Parker

    Keren Sturtz
    Ph: 888-785-6789

    Pueblo

    Rocky Mountain Cancer Centers - Pueblo

    Keren Sturtz
    Ph: 888-785-6789

    St. Mary - Corwin Regional Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Thornton

    Rocky Mountain Cancer Centers - Thornton

    Keren Sturtz
    Ph: 888-785-6789

    Wheat Ridge

    Exempla Lutheran Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Connecticut
    Bridgeport

    St. Vincent's Medical Center

    Paul E Berard
    Ph: 203-576-6329
    Email: twhite@stvincents.org

    Farmington

    Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center

    Angela S Kueck
    Ph: 800-579-7822

    Hartford

    Helen and Harry Gray Cancer Center at Hartford Hospital

    James S. Hoffman
    Ph: 860-224-5660

    Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Middletown

    Middlesex Hospital Cancer Center

    Susanna Hong
    Ph: 860-358-2058

    New Britain

    George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus

    James S. Hoffman
    Ph: 860-224-5660

    Delaware
    Lewes

    Tunnell Cancer Center at Beebe Medical Center

    Mark E Borowsky
    Ph: 302-733-6227

    Newark

    Christiana Gynecologic Oncology, LLC

    Mark E Borowsky
    Ph: 302-733-6227

    Delaware Clinical and Laboratory Physicians

    Mark E Borowsky
    Ph: 302-733-6227

    Helen F. Graham Cancer Center at Christiana Hospital

    Mark E Borowsky
    Ph: 302-733-6227

    Mark E Borowsky
    Ph: 302-733-6227

    Medical Oncology Hematology Consultants, PA at Helen F. Graham Cancer Center

    Mark E Borowsky
    Ph: 302-733-6227

    Regional Hematology/Oncology, PA - Newark

    Mark E Borowsky
    Ph: 302-733-6227

    Rehoboth Beach

    Beebe Health Campus

    Mark E Borowsky
    Ph: 302-733-6227

    Seaford

    Nanticoke Memorial Hospital

    Mark E Borowsky
    Ph: 302-733-6227

    Wilmington

    Christiana Care Health System-Wilmington Hospital

    Mark E Borowsky
    Ph: 302-733-6227

    Florida
    Fort Myers

    Florida Gynecologic Oncology - Fort Myers

    Edward C. Grendys
    Ph: 800-874-7502

    Georgia
    Augusta

    Medical College of Georgia Cancer Center

    Sharad Anant Ghamande
    Ph: 706-721-1663
    Email: cancer@georgiahealth.edu

    Columbus

    John B. Amos Cancer Center

    Gregory P Sfakianos
    Ph: 706-660-6404

    Gainesville

    Northeast Georgia Medical Center

    Andrew E Green
    Ph: 770-219-8800
    Email: cancerpatient.navigator@nghs.com

    Savannah

    Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center

    James J Burke
    Ph: 912-350-8568

    Low Country Cancer Care Associates, PC

    James J Burke
    Ph: 912-350-8568

    Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler

    William Edward Richards
    Ph: 800-622-6877

    Summit Cancer Care-Memorial

    James J Burke
    Ph: 912-350-8568

    Idaho
    Boise

    Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Illinois
    Aurora

    Rush-Copley Cancer Care Center

    Kendrith M. Rowland
    Ph: 800-446-5532

    Bloomington

    Illinois CancerCare - Bloomington

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    St. Joseph Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Canton

    Illinois CancerCare - Canton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Carbondale

    Memorial Hospital of Carbondale

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Carthage

    Illinois CancerCare - Carthage

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Centralia

    Centralia Oncology Clinic

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Chicago

    Robert H. Lurie Comprehensive Cancer Center at Northwestern University

    Emily Berry
    Ph: 312-695-1301
    Email: cancer@northwestern.edu

    University of Chicago Cancer Research Center

    Meaghan E Tenney
    Ph: 773-834-7424

    Danville

    Carle on Vermilion

    Kendrith M. Rowland
    Ph: 800-446-5532

    Decatur

    Cancer Care Center of Decatur

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Decatur Memorial Hospital Cancer Care Institute

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Effingham

    Carle Physician Group-Effingham

    Kendrith M. Rowland
    Ph: 800-446-5532

    Crossroads Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Eureka

    Illinois CancerCare - Eureka

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Galesburg

    Galesburg Clinic, PC

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    InterCommunity Cancer Center of Western Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Hinsdale

    Gynecologic Oncology

    Sudarshan K. Sharma
    Ph: 630-856-6757

    Kewanee

    Illinois CancerCare - Kewanee Clinic

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Macomb

    Illinois CancerCare - Macomb

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Mattoon

    Carle Physician Group-Mattoon/Charleston

    Kendrith M. Rowland
    Ph: 800-446-5532

    Mount Vernon

    Good Samaritan Regional Health Center

    Jay W Carlson
    Ph: 800-821-7532

    New Lennox

    Silver Cross Hospital

    Meaghan E Tenney
    Ph: 773-834-7424

    Ottawa

    Illinois CancerCare - Ottawa

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Radiation Oncology of Northern Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Pekin

    Cancer Treatment Center at Pekin Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Illinois CancerCare - Pekin

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Peoria

    Illinois CancerCare - Peoria

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Methodist Medical Center of Illinois

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    OSF St. Francis Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Peru

    Illinois CancerCare - Princeton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Valley Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Princeton

    Illinois CancerCare - Princeton

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Springfield

    Central Illinois Hematology Oncology Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Regional Cancer Center at Memorial Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Simmons Cooper Cancer Institute

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Springfield Clinic - Main Campus

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Swansea

    Cancer Care Specialists of Illinois-Swansea

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Urbana

    Carle Cancer Center at Carle Foundation Hospital

    Kendrith M. Rowland
    Ph: 800-446-5532

    Kendrith M. Rowland
    Ph: 800-446-5532

    Yorkville

    Rush-Copley Healthcare Center

    Kendrith M. Rowland
    Ph: 800-446-5532

    Indiana
    Elkhart

    Michiana Hematology-Oncology, PC - Elkhart

    Michael Rodriguez
    Ph: 574-237-1328

    Indianapolis

    Indiana University Melvin and Bren Simon Cancer Center

    Jeanne M Schilder
    Ph: 317-274-2552

    Michigan City

    Saint Anthony Memorial Health Centers

    Kendrith M. Rowland
    Ph: 800-446-5532

    Woodland Cancer Care Center

    Kendrith M. Rowland
    Ph: 800-446-5532

    Mishawaka

    Michiana Hematology-Oncology, PC - Mishawaka

    Michael Rodriguez
    Ph: 574-237-1328

    Munster

    Community Hospital

    Mohamad Kassar
    Ph: 219-836-3349

    Plymouth

    Michiana Hematology Oncology PC - Plymouth

    Michael Rodriguez
    Ph: 574-237-1328

    Richmond

    Reid Hospital & Health Care Services

    Howard M. Gross
    Ph: 937-775-1350

    South Bend

    CCOP - Northern Indiana CR Consortium

    Michael Rodriguez
    Ph: 574-237-1328

    Michiana Hematology-Oncology, PC - South Bend

    Michael Rodriguez
    Ph: 574-237-1328

    Westville

    Michiana Hematology Oncology-PC Westville

    Michael Rodriguez
    Ph: 574-237-1328

    Iowa
    Clive

    Medical Oncology and Hematology Associates-West Des Moines

    Mehmet S. Copur
    Ph: 800-998-2119

    Mercy Cancer Center - West Lakes

    Mehmet S. Copur
    Ph: 800-998-2119

    Council Bluffs

    Alegent Health Mercy Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Des Moines

    CCOP - Iowa Oncology Research Association

    Robert J Behrens
    Ph: 515-282-2921

    John Stoddard Cancer Center at Iowa Lutheran Hospital

    Robert J Behrens
    Ph: 515-282-2921

    John Stoddard Cancer Center at Iowa Methodist Medical Center

    Robert J Behrens
    Ph: 515-282-2921

    Medical Oncology and Hematology Associates at John Stoddard Cancer Center

    Robert J Behrens
    Ph: 515-282-2921

    Medical Oncology and Hematology Associates at Mercy Cancer Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Mercy Cancer Center at Mercy Medical Center - Des Moines

    Mehmet S. Copur
    Ph: 800-998-2119

    Iowa City

    Holden Comprehensive Cancer Center at University of Iowa

    David P Bender
    Ph: 800-237-1225

    West Des Moines

    Methodist West Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Robert J Behrens
    Ph: 515-282-2921

    Kansas
    Chanute

    Cancer Center of Kansas, PA - Chanute

    Shaker R. Dakhil
    Ph: 316-262-4467

    Dodge City

    Cancer Center of Kansas, PA - Dodge City

    Shaker R. Dakhil
    Ph: 316-262-4467

    El Dorado

    Cancer Center of Kansas, PA - El Dorado

    Shaker R. Dakhil
    Ph: 316-262-4467

    Fort Scott

    Cancer Center of Kansas - Fort Scott

    Shaker R. Dakhil
    Ph: 316-262-4467

    Independence

    Cancer Center of Kansas-Independence

    Shaker R. Dakhil
    Ph: 316-262-4467

    Kansas City

    Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Kingman

    Cancer Center of Kansas, PA - Kingman

    Shaker R. Dakhil
    Ph: 316-262-4467

    Lawrence

    Lawrence Memorial Hospital

    Shaker R. Dakhil
    Ph: 316-262-4467

    Liberal

    Cancer Center of Kansas, PA - Liberal

    Shaker R. Dakhil
    Ph: 316-262-4467

    Newton

    Cancer Center of Kansas, PA - Newton

    Shaker R. Dakhil
    Ph: 316-262-4467

    Overland Park

    Menorah Medical Center

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Saint Luke's Hospital - South

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Parsons

    Cancer Center of Kansas, PA - Parsons

    Shaker R. Dakhil
    Ph: 316-262-4467

    Pratt

    Cancer Center of Kansas, PA - Pratt

    Shaker R. Dakhil
    Ph: 316-262-4467

    Salina

    Cancer Center of Kansas, PA - Salina

    Shaker R. Dakhil
    Ph: 316-262-4467

    Wellington

    Cancer Center of Kansas, PA - Wellington

    Shaker R. Dakhil
    Ph: 316-262-4467

    Wichita

    Associates in Women's Health, PA - North Hillside

    Shaker R. Dakhil
    Ph: 316-262-4467

    Cancer Center of Kansas, PA - Medical Arts Tower

    Shaker R. Dakhil
    Ph: 316-262-4467

    Cancer Center of Kansas, PA - Wichita

    Shaker R. Dakhil
    Ph: 316-262-4467

    Via Christi Cancer Center at Via Christi Regional Medical Center

    Shaker R. Dakhil
    Ph: 316-262-4467

    Winfield

    Cancer Center of Kansas, PA - Winfield

    Shaker R. Dakhil
    Ph: 316-262-4467

    Kentucky
    Bardstown

    Flaget Memorial Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Corbin

    Commonwealth Cancer Center-Corbin

    Mehmet S. Copur
    Ph: 800-998-2119

    Crestview Hills

    Oncology Hematology Care, Incorporated - Crestview Hills

    Howard M. Gross
    Ph: 937-775-1350

    Lexington

    Saint Joseph East

    Mehmet S. Copur
    Ph: 800-998-2119

    United Radiation Oncology - Bob-O-Link Drive Office

    Mehmet S. Copur
    Ph: 800-998-2119

    Louisville

    Jewish Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Jewish Hospital Medical Center Northeast

    Mehmet S. Copur
    Ph: 800-998-2119

    Saints Mary and Elizabeth Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    University of Louisville School of Medicine

    Lynn P Parker
    Ph: 866-530-5516

    Shepherdsville

    Jewish Hospital Medical Center South

    Mehmet S. Copur
    Ph: 800-998-2119

    Louisiana
    Baton Rouge

    Hematology-Oncology Clinic

    William R. Robinson
    Ph: 504-988-6121

    Pennington Cancer Center at Baton Rouge General

    William R. Robinson
    Ph: 504-988-6121

    Woman's Hospital

    Giles Fort
    Ph: 225-231-5296
    Email: Ericka.Seidemann@womans.org

    Marrero

    West Jefferson Medical Center

    William R. Robinson
    Ph: 504-988-6121

    New Orleans

    Tulane Cancer Center at Tulane University Hospital and Clinic

    William R. Robinson
    Ph: 504-988-6121

    Maryland
    Baltimore

    Alvin and Lois Lapidus Cancer Institute at Sinai Hospital

    Fouad M Abbas
    Ph: 410-601-6120
    Email: pridgely@lifebridgehealth.org

    Greater Baltimore Medical Center Cancer Center

    Amanda N Fader
    Ph: 410-955-8804
    Email: jhcccro@jhmi.edu

    Bethesda

    National Naval Medical Center

    Michael P Stany
    Ph: 301-319-2100

    Randallstown

    Northwest Hospital Center

    Fouad M Abbas
    Ph: 410-601-6120
    Email: pridgely@lifebridgehealth.org

    Massachusetts
    Worcester

    Levine Cancer Center at UMass Medical Center - Memorial Campus

    Susan L. Zweizig
    Ph: 508-856-3216
    Email: cancer.research@umassmed.edu

    Michigan
    Ann Arbor

    Saint Joseph Mercy Cancer Center

    Philip J. Stella
    Ph: 734-712-4673

    University of Michigan Comprehensive Cancer Center

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Battle Creek

    Battle Creek Health System Cancer Care Center

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Dearborn

    Oakwood Cancer Center at Oakwood Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Detroit

    Josephine Ford Cancer Center at Henry Ford Hospital

    Thomas E Buekers
    Ph: 313-916-1784

    Van Elslander Cancer Center at St. John Hospital and Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Wayne State University

    Robert T. Morris
    Ph: 313-576-9363

    Escanaba

    Green Bay Oncology, Limited - Escanaba

    Jonathan E Tammela
    Ph: 920-433-8889

    Farmington Hills

    Weisberg Cancer Treatment Center

    Robert T. Morris
    Ph: 313-576-9363

    Flint

    Genesys Hurley Cancer Institute

    Philip J. Stella
    Ph: 734-712-4673

    Hurley Medical Center

    Philip J. Stella
    Ph: 734-712-4673

    Grand Rapids

    Butterworth Hospital at Spectrum Health

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Lacks Cancer Center at Saint Mary's Health Care

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Iron Mountain

    Green Bay Oncology - Iron Mountain

    Jonathan E Tammela
    Ph: 920-433-8889

    Jackson

    Gayle M. Jacob Cancer Center at Allegiance Health

    Philip J. Stella
    Ph: 734-712-4673

    Kalamazoo

    West Michigan Cancer Center

    Sunil Nagpal
    Ph: 269-373-7458

    Lansing

    Sparrow Regional Cancer Center

    Philip J. Stella
    Ph: 734-712-4673

    Livonia

    St. Mary Mercy Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Muskegon

    Mercy General Health Partners

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Niles

    Lakeland Hospital - Niles

    Michael Rodriguez
    Ph: 574-237-1328

    Pontiac

    St. Joseph Mercy Oakland

    Philip J. Stella
    Ph: 734-712-4673

    Port Huron

    Mercy Regional Cancer Center at Mercy Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Reed City

    Spectrum Health Reed City Hospital

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Saginaw

    Seton Cancer Institute at Saint Mary's - Saginaw

    Philip J. Stella
    Ph: 734-712-4673

    Saint Joseph

    Lakeside Cancer Specialists, PLLC

    Michael Rodriguez
    Ph: 574-237-1328

    St. Joseph

    Lakeland Regional Cancer Care Center - St. Joseph

    Michael Rodriguez
    Ph: 574-237-1328

    Traverse City

    Munson Medical Center

    Gilbert D Padula
    Ph: 616-685-5225
    Email: connie.szczepanek@grcop.org

    Warren

    St. John Macomb Hospital

    Philip J. Stella
    Ph: 734-712-4673

    Minnesota
    Bemidji

    MeritCare Bemidji

    Maria C. Bell
    Ph: 218-333-5000

    Burnsville

    Fairview Ridges Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Coon Rapids

    Mercy and Unity Cancer Center at Mercy Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Edina

    Fairview Southdale Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Fridley

    Mercy and Unity Cancer Center at Unity Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Hutchinson

    Hutchinson Area Health Care

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Maplewood

    HealthEast Cancer Care at St. John's Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Minnesota Oncology - Maplewood

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Minneapolis

    Health Partners Inc

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Hennepin County Medical Center - Minneapolis

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Virginia Piper Cancer Institute at Abbott - Northwestern Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    New Ulm

    New Ulm Medical Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Robbinsdale

    Humphrey Cancer Center at North Memorial Outpatient Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Saint Louis Park

    Park Nicollet Cancer Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Saint Paul

    Regions Hospital Cancer Care Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    United Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Shakopee

    St. Francis Cancer Center at St. Francis Medical Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Stillwater

    Lakeview Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Waconia

    Ridgeview Medical Center

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Willmar

    Willmar Cancer Center at Rice Memorial Hospital

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Woodbury

    Minnesota Oncology - Woodbury

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Mississippi
    Jackson

    St. Dominic Cancer Center

    Donald P Seago
    Ph: 601-200-3300

    University of Mississippi Cancer Clinic

    James Tate Thigpen
    Ph: 601-815-6700

    Pascagoula

    Regional Cancer Center at Singing River Hospital

    James E. Clarkson
    Ph: 228-809-5292

    Missouri
    Bolivar

    Central Care Cancer Center at Carrie J. Babb Cancer Center

    Jay W Carlson
    Ph: 800-821-7532

    Bonne Terre

    Parkland Health Center-Bonne Terre

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Branson

    Skaggs Cancer Center at Skaggs Regional Medical Center

    Jay W Carlson
    Ph: 800-821-7532

    Cape Girardeau

    Saint Francis Medical Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Southeast Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Columbia

    Ellis Fischel Cancer Center at University of Missouri - Columbia

    Mark I Hunter
    Ph: 573-882-7440

    Independence

    Independence Regional Health Center

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Jefferson City

    Goldschmidt Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Joplin

    Freeman Cancer Institute at Freeman Health System

    Jay W Carlson
    Ph: 800-821-7532

    St. John's Regional Medical Center

    Jay W Carlson
    Ph: 800-821-7532

    Kansas City

    Heartland Hematology Oncology Associates, Incorporated

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Research Medical Center

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Saint Luke's Hospital

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Lee's Summit

    Saint Luke's East - Lee's Summit

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Liberty

    Parvin Radiation Oncology

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Rolla

    Mercy Clinic Cancer and Hematology - Rolla

    Jay W Carlson
    Ph: 800-821-7532

    Phelps County Regional Medical Center

    Jay W Carlson
    Ph: 800-821-7532

    Saint Joseph

    Heartland Regional Medical Center

    Rakesh Gaur
    Ph: 913-948-5588
    Email: aroland@kccop.org

    Saint Louis

    David C. Pratt Cancer Center at St. John's Mercy

    Jay W Carlson
    Ph: 800-821-7532

    Mercy Clinic St. Louis Cancer and Breast Institute

    Jay W Carlson
    Ph: 800-821-7532

    Missouri Baptist Cancer Center

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Sainte Genevieve

    Sainte Genevieve County Memorial Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Springfield

    Hulston Cancer Center at Cox Medical Center South

    Jay W Carlson
    Ph: 800-821-7532

    St. John's Regional Health Center

    Jay W Carlson
    Ph: 800-821-7532

    Sullivan

    Missouri Baptist Sullivan Hospital

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Sunset Hills

    Missouri Baptist Outpatient Center-Sunset Hills

    James L. Wade
    Ph: 217-876-4740
    Email: kcheek@dmhhs.org

    Nebraska
    Grand Island

    Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Kearney

    Good Samaritan Cancer Center at Good Samaritan Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Heartland Hematology and Oncology

    Mehmet S. Copur
    Ph: 800-998-2119

    Lincoln

    Saint Elizabeth Cancer Institute at Saint Elizabeth Regional Medical Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Omaha

    Alegant Health Cancer Center at Bergan Mercy Medical Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Creighton University Medical Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Hematology/Oncology Consultants

    Mehmet S. Copur
    Ph: 800-998-2119

    Immanuel Medical Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Lakeside Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Methodist Estabrook Cancer Center

    Peter C. Morris
    Ph: 402-354-7939
    Email: kathryn.bartz@nmhs.org

    Papillion

    Midlands Cancer Center at Midlands Community Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Nevada
    Las Vegas

    Women's Cancer Center - La Canada

    Nick M. Spirtos
    Ph: 702-851-4672

    Reno

    Renown Institute for Cancer at Renown Regional Medical Center

    Peter C Lim
    Ph: 866-513-8227

    Peter C Lim
    Ph: 866-513-8227

    New Jersey
    Camden

    Cancer Institute of New Jersey at Cooper University Hospital - Camden

    David P. Warshal
    Ph: 856-325-6757

    Morristown

    Carol G. Simon Cancer Center at Morristown Memorial Hospital

    Daniel H Tobias
    Ph: 973-971-5900

    Mount Holly

    Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County

    Randolph B Deger
    Ph: 888-847-8823

    Neptune

    Jersey Shore Cancer Center at Jersey Shore University Medical Center

    Karim S ElSahwi
    Ph: 732-776-4240

    New Brunswick

    Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School

    Darlene G. Gibbon
    Ph: 732-235-8675

    Phillipsburg

    Women’s Institute for Gynecologic Cancer and Special Pelvic Surgery

    David Foster Silver
    Ph: 718-765-2500

    Summit

    Overlook Hospital

    Daniel H Tobias
    Ph: 973-971-5900

    Voorhees

    Cancer Institute of New Jersey at Cooper - Voorhees

    David P. Warshal
    Ph: 856-325-6757

    Fox Chase Virtua Health Cancer Program at Virtua West Jersey

    Randolph B Deger
    Ph: 888-847-8823

    New Mexico
    Albuquerque

    Southwest Gynecologic Oncology Associates, Incorporated

    Carolyn Y. Muller
    Ph: 505-272-6972

    University of New Mexico Cancer Center

    Carolyn Y. Muller
    Ph: 505-272-6972

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Las Cruces

    Memorial Medical Center

    Carolyn Y. Muller
    Ph: 505-272-6972

    New York
    Albany

    Women's Cancer Care Associates

    Daniel Casey Kredentser
    Ph: 518-458-1390

    Brooklyn

    New York Methodist Hospital

    Katherine Economos
    Ph: 718-780-5240

    SUNY Downstate Medical Center

    Ovadia Abulafia
    Ph: 718-270-8216
    Email: sima.terebelo@downstate.edu

    Manhasset

    Don Monti Comprehensive Cancer Center at North Shore University Hospital

    Veena S John
    Ph: 516-562-3467

    New Hyde Park

    Long Island Jewish Medical Center

    Veena S John
    Ph: 516-562-3467

    Monter Cancer Center of the North Shore-LIJ Health System

    Veena S John
    Ph: 516-562-3467

    New York

    Mount Sinai Medical Center

    Jamal Rahaman
    Ph: 212-824-7320
    Email: jenny.figueroa@mssm.edu

    New York University Medical Center

    Stephanie V. Blank
    Ph: 212-263-4434
    Email: prmc.coordinator@nyumc.org

    Stony Brook

    Stony Brook University Cancer Center

    Michael L. Pearl
    Ph: 800-862-2215

    Syracuse

    SUNY Upstate Medical University Hospital

    Mary J Cunningham
    Ph: 315-464-5476

    North Carolina
    Asheboro

    Randolph Hospital

    James M Granfortuna
    Ph: 336-832-0821

    Burlington

    Alamance Cancer Center at Alamance Regional Medical Center

    James M Granfortuna
    Ph: 336-832-0821

    Charlotte

    Blumenthal Cancer Center at Carolinas Medical Center

    Robert Victor Higgins
    Ph: 704-355-2884

    Presbyterian Cancer Center at Presbyterian Hospital

    John M McDonald
    Ph: 704-384-5369

    Durham

    Duke Cancer Institute

    Angeles Alvarez Secord
    Ph: 888-275-3853

    Greensboro

    Moses Cone Regional Cancer Center at Wesley Long Community Hospital

    James M Granfortuna
    Ph: 336-832-0821

    Mebane

    Cone Heath Cancer Center at Mebane

    James M Granfortuna
    Ph: 336-832-0821

    Pinehurst

    FirstHealth Moore Regional Community Hospital Comprehensive Cancer Center

    Michael J Sundborg
    Ph: 910-715-2200

    Raleigh

    Duke Health Raleigh Hospital

    Angeles Alvarez Secord
    Ph: 888-275-3853

    Reidsville

    Annie Penn Cancer Center

    James M Granfortuna
    Ph: 336-832-0821

    Winston-Salem

    Wake Forest University Comprehensive Cancer Center

    Samuel S. Lentz
    Ph: 336-713-6771

    North Dakota
    Fargo

    Roger Maris Cancer Center at MeritCare Hospital

    Maria C. Bell
    Ph: 218-333-5000

    Maria C. Bell
    Ph: 218-333-5000

    Sanford Clinic North-Fargo

    Maria C. Bell
    Ph: 218-333-5000

    Ohio
    Akron

    Summa Center for Cancer Care at Akron City Hospital

    Vivian von Gruenigen
    Ph: 330-375-6101

    Belpre

    Strecker Cancer Center-Belpre

    J. Philip Kuebler
    Ph: 614-566-3275

    Canton

    Aultman Cancer Center at Aultman Hospital

    Michael P. Hopkins
    Ph: 330-363-6891

    Centerville

    Miami Valley Hospital South

    Howard M. Gross
    Ph: 937-775-1350

    Chillicothe

    Adena Regional Medical Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Cincinnati

    Bethesda North Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Good Samaritan Hospital Cancer Treatment Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Oncology Hematology Care Inc - Western Hills

    Howard M. Gross
    Ph: 937-775-1350

    Oncology Hematology Care, Incorporated - Anderson

    Howard M. Gross
    Ph: 937-775-1350

    Oncology Hematology Care, Incorporated - Blue Ash

    Howard M. Gross
    Ph: 937-775-1350

    Oncology Hematology Care, Incorporated - Kenwood

    Howard M. Gross
    Ph: 937-775-1350

    Oncology Hematology Care, Incorporated - Mt. Auburn/Taft Road

    Howard M. Gross
    Ph: 937-775-1350

    TriHealth Cancer Institute-Anderson

    Mehmet S. Copur
    Ph: 800-998-2119

    TriHealth Cancer Institute-Westside

    Mehmet S. Copur
    Ph: 800-998-2119

    University of Cincinnati

    Eric L Eisenhauer
    Ph: 513-558-4553
    Email: uchealthnews@uc.edu

    Cleveland

    Case Comprehensive Cancer Center

    Steven E. Waggoner
    Ph: 800-641-2422

    Cleveland Clinic Cancer Center at Fairview Hospital

    Peter Graham Rose
    Ph: 866-223-8100

    Cleveland Clinic Taussig Cancer Center

    Peter Graham Rose
    Ph: 866-223-8100

    Columbus

    Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Columbus Oncology Associates, Incorporated

    J. Philip Kuebler
    Ph: 614-566-3275

    Doctors Hospital at Ohio Health

    J. Philip Kuebler
    Ph: 614-566-3275

    Grant Medical Center Cancer Care

    J. Philip Kuebler
    Ph: 614-566-3275

    Mount Carmel Health - West Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Riverside Methodist Hospital Cancer Care

    J. Philip Kuebler
    Ph: 614-566-3275

    Zangmeister Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Dayton

    David L. Rike Cancer Center at Miami Valley Hospital

    Howard M. Gross
    Ph: 937-775-1350

    Good Samaritan Hospital

    Howard M. Gross
    Ph: 937-775-1350

    Samaritan North Cancer Care Center

    Howard M. Gross
    Ph: 937-775-1350

    Delaware

    Delaware Health Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Delaware Radiation Oncology

    J. Philip Kuebler
    Ph: 614-566-3275

    Grady Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Fairfield

    Oncology Hematology Care, Incorporated - Fairfield Healthplex

    Howard M. Gross
    Ph: 937-775-1350

    Findlay

    Blanchard Valley Regional Cancer Center

    Howard M. Gross
    Ph: 937-775-1350

    Franklin

    Atrium Medical Center

    Howard M. Gross
    Ph: 937-775-1350

    Greenville

    Wayne Hospital

    Howard M. Gross
    Ph: 937-775-1350

    Kettering

    Charles F. Kettering Memorial Hospital

    Howard M. Gross
    Ph: 937-775-1350

    Lancaster

    Fairfield Medical Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Marietta

    Strecker Cancer Center at Marietta Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Mayfield Heights

    Hillcrest Cancer Center at Hillcrest Hospital

    Peter Graham Rose
    Ph: 866-223-8100

    Mentor

    Lake/University Ireland Cancer Center

    Steven E. Waggoner
    Ph: 800-641-2422

    Mount Vernon

    Knox Community Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Newark

    Licking Memorial Cancer Care Program at Licking Memorial Hospital

    J. Philip Kuebler
    Ph: 614-566-3275

    Newark Radiation Oncology

    J. Philip Kuebler
    Ph: 614-566-3275

    Portsmouth

    Southern Ohio Medical Center Cancer Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Springfield

    Community Hospital of Springfield and Clark County

    J. Philip Kuebler
    Ph: 614-566-3275

    Troy

    UVMC Cancer Care Center at Upper Valley Medical Center

    Howard M. Gross
    Ph: 937-775-1350

    Westerville

    Mount Carmel St. Ann's Cancer Center

    J. Philip Kuebler
    Ph: 614-566-3275

    Wright-Patterson Afb

    United States Air Force Medical Center - Wright-Patterson

    Yovanni Casablanca
    Ph: 937-257-1398

    Zanesville

    Genesis - Good Samaritan Hospital

    J. Philip Kuebler
    Ph: 614-488-2745
    Email: sheree@columbusccop.org

    Oklahoma
    Oklahoma City

    Stephenson Cancer Center at the University of Oklahoma

    Robert S. Mannel
    Ph: 405-271-4272
    Email: julie-traylor@ouhsc.edu

    Tulsa

    Cancer Care Associates-Yale

    Robert S. Mannel
    Ph: 405-271-4272
    Email: julie-traylor@ouhsc.edu

    Oregon
    Clackamas

    Clackamas Radiation Oncology Center

    Alison K Conlin
    Ph: 503-215-6412

    Providence Oncology and Hematology Care Southeast

    Alison K Conlin
    Ph: 503-215-6412

    Newberg

    Providence Newberg Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Oregon City

    Willamette Falls Hospital

    Alison K Conlin
    Ph: 503-215-6412

    Portland

    Knight Cancer Institute at Oregon Health and Science University

    Tanja Pejovic
    Ph: 503-494-1080
    Email: trials@ohsu.edu

    Providence Cancer Center at Providence Portland Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Providence St. Vincent Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Pennsylvania
    Abington

    Rosenfeld Cancer Center at Abington Memorial Hospital

    Parviz Hanjani
    Ph: 215-481-2402

    Allentown

    Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest

    Alyson F McIntosh
    Ph: 610-402-2273

    Bethlehem

    Lehigh Valley Hospital - Muhlenberg

    Alyson F McIntosh
    Ph: 610-402-2273

    St. Luke's Cancer Network at St. Luke's Hospital

    Nicholas P Taylor
    Ph: 610-954-3582
    Email: infolink@slhn.org

    Danville

    Geisinger Cancer Institute at Geisinger Health

    Radhika P Gogoi
    Ph: 570-271-5251

    Hazleton

    Geisinger Hazleton Cancer Center

    Radhika P Gogoi
    Ph: 570-271-5251

    Hershey

    Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center

    James Fanning
    Ph: 717-531-3779
    Email: CTO@hmc.psu.edu

    Philadelphia

    Abramson Cancer Center of the University of Pennsylvania

    Robert A. Burger
    Ph: 215-746-7406

    Fox Chase Cancer Center - Philadelphia

    Stephen C. Rubin
    Ph: 215-728-4790

    Joan Karnell Cancer Center at Pennsylvania Hospital

    Patricia A. Ford
    Ph: 800-474-9892

    Temple Cancer Center at Temple University Hospital

    Enrique Hernandez
    Ph: 215-728-2983

    Pittsburgh

    Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital

    Thomas C Krivak
    Ph: 412-578-5000

    State College

    Geisinger Medical Group - Scenery Park

    Radhika P Gogoi
    Ph: 570-271-5251

    West Reading

    McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center

    Bernice L Robinson-Bennett
    Ph: 610-988-9323

    Wilkes-Barre

    Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center

    Radhika P Gogoi
    Ph: 570-271-5251

    Rhode Island
    Providence

    Women and Infants Hospital of Rhode Island

    Paul A. DiSilvestro
    Ph: 401-274-1122

    South Dakota
    Rapid City

    Black Hills Obstetrics & Gynecology LLP

    Helen L. Frederickson
    Ph: 605-343-9224

    Rapid City Regional Hospital

    Helen L. Frederickson
    Ph: 605-343-9224

    Sioux Falls

    Avera Cancer Institute

    Luis A Rojas-Espaillat
    Ph: 800-657-4377
    Email: Jan.Healy@avera.org

    Sanford Cancer Center at Sanford USD Medical Center

    Maria C. Bell
    Ph: 218-333-5000

    Maria C. Bell
    Ph: 218-333-5000

    Tennessee
    Bristol

    Blue Ridge Medical Specialists, PC

    Asheesh Shipstone
    Ph: 423-578-8538

    Wellmont-Bristol Regional Medical Center

    Asheesh Shipstone
    Ph: 423-578-8538

    Chattanooga

    H. Clay Evans Johnson Cancer Center at Memorial Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Hixson

    Pulmonary Medicine Center of Chattanooga-Hixson

    Mehmet S. Copur
    Ph: 800-998-2119

    Johnson City

    Wellmont Medical Associates Oncology and Hematology-Johnson City

    Asheesh Shipstone
    Ph: 423-578-8538

    Kingsport

    Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center

    Asheesh Shipstone
    Ph: 423-578-8538

    Kingsport Hematology-Oncology Associates

    Asheesh Shipstone
    Ph: 423-578-8538

    Ooltewah

    Memorial GYN Plus

    Mehmet S. Copur
    Ph: 800-998-2119

    Texas
    Austin

    University Medical Center Brackenridge

    Mark A Crozier
    Ph: 512-324-7991

    Dallas

    Parkland Memorial Hospital

    David Scott Miller
    Ph: 214-648-7097

    Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

    David Scott Miller
    Ph: 214-648-7097

    Fort Sam Houston

    Brooke Army Medical Center

    Jason C Barnett
    Ph: 210-916-4837

    Galveston

    University of Texas Medical Branch

    Lyuba Levine
    Ph: 409-772-1950
    Email: clinical.research@utmb.edu

    Houston

    Lyndon B. Johnson General Hospital

    Lois M. Ramondetta
    Ph: 713-792-3245

    Memorial Hermann - Texas Medical Center

    Anthony Lucci
    Ph: 866-574-5124
    Email: Sylvester@emergingmed.com

    Methodist Hospital

    Aparna A Kamat
    Ph: 713-790-2700

    Univeristy of Texas M.D. Anderson Cancer Center

    Robert L. Coleman
    Ph: 713-792-3245

    Utah
    American Fork

    American Fork Hospital

    Ross E. Morgan
    Ph: 801-581-4477
    Email: clinical.trials@hci.utah.edu

    Vermont
    Burlington

    University of Vermont Medical Center

    Cheung Wong
    Ph: 802-656-8990

    Virginia
    Charlottesville

    University of Virginia Cancer Center

    Susan C Modesitt
    Ph: 434-243-6143

    Norton

    Southwest Virginia Regional Cancer Center at Wellmonth Health

    Asheesh Shipstone
    Ph: 423-578-8538

    Richmond

    Virginia Commonwealth University Massey Cancer Center

    Weldon E Chafe
    Ph: 804-628-1939

    Roanoke

    Carilion Clinic Gynecological Oncology

    Janet L. Osborne
    Ph: 540-985-8510

    Washington
    Bremerton

    Harrison Medical Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Olympic Hematology and Oncology

    Mehmet S. Copur
    Ph: 800-998-2119

    Burien

    Highline Medical Center Cancer Center

    Mehmet S. Copur
    Ph: 800-998-2119

    Enumclaw

    Saint Elizabeth Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Federal Way

    St. Francis Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Issaquah

    Swedish Medical Center - Issaquah Campus

    Heidi J Gray
    Ph: 206-616-8289

    Lakewood

    St. Clare Hospital

    Mehmet S. Copur
    Ph: 800-998-2119

    Longview

    Lower Columbia Regional Cancer Center at PeaceHealth-St. John Medical Center

    Alison K Conlin
    Ph: 503-215-6412

    Mount Vernon

    Skagit Valley Hospital Cancer Care Center

    Benjamin E. Greer
    Ph: 206-616-8289

    Poulsbo

    Harrison Poulsbo Hematology and Onocology

    Mehmet S. Copur
    Ph: 800-998-2119

    Seattle

    CCOP - Virginia Mason Research Center

    Amy D Brockmeyer
    Ph: 206-342-6954
    Email: vmmc.cancer_clinical_research@VirginiaMason.org

    Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

    Benjamin E. Greer
    Ph: 206-616-8289

    Pacific Gynecology Specialists

    Benjamin E. Greer
    Ph: 206-616-8289

    Seattle Cancer Care Alliance

    Benjamin E. Greer
    Ph: 206-616-8289

    Swedish Cancer Institute at Swedish Medical Center - First Hill Campus

    Heidi J Gray
    Ph: 206-616-8289

    Swedish Cancer Institute at Northwest Hospital & Medical Center

    Benjamin E. Greer
    Ph: 206-616-8289

    University Cancer Center at University of Washington Medical Center

    Benjamin E. Greer
    Ph: 206-616-8289

    Virginia Mason Medical Center

    Amy D Brockmeyer
    Ph: 206-342-6954
    Email: vmmc.cancer_clinical_research@VirginiaMason.org

    Sequim

    Olympic Medical Cancer Center

    Benjamin E. Greer
    Ph: 206-616-8289

    Spokane

    Cancer Care Northwest - North

    Heidi J Gray
    Ph: 206-616-8289

    Cancer Care Northwest - Spokane South

    Benjamin E. Greer
    Ph: 206-616-8289

    Cancer Care Northwest - Valley

    Heidi J Gray
    Ph: 206-616-8289

    Tacoma

    Franciscan Research Center-Northwest Medical Plaza

    Mehmet S. Copur
    Ph: 800-998-2119

    Northwest Medical Specialties, PLLC - Tacoma

    Mehmet S. Copur
    Ph: 800-998-2119

    Vancouver

    Southwest Washington Medical Center Cancer Center

    Alison K Conlin
    Ph: 503-215-6412

    Wenatchee

    Confluence Health - Wenatchee Valley Medical Center

    Heidi J Gray
    Ph: 206-616-8289

    Wisconsin
    Fond Du Lac

    Aurora Health Center-Fond du Lac

    Ali Mahdavi
    Ph: 414-649-5717

    Green Bay

    Green Bay Oncology, Limited at St. Mary's Hospital

    Jonathan E Tammela
    Ph: 920-433-8889

    Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center

    Jonathan E Tammela
    Ph: 920-433-8889

    St. Mary's Hospital Medical Center - Green Bay

    Jonathan E Tammela
    Ph: 920-433-8889

    St. Vincent Hospital Regional Cancer Center

    Jonathan E Tammela
    Ph: 920-433-8889

    Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center

    Ali Mahdavi
    Ph: 414-649-5717

    Madison

    University of Wisconsin Paul P. Carbone Comprehensive Cancer Center

    David M Kushner
    Ph: 877-405-6866

    Marinette

    Bay Area Cancer Care Center at Bay Area Medical Center

    Jonathan E Tammela
    Ph: 920-433-8889

    Vince Lombardi Cancer Clinic - Marinette

    Ali Mahdavi
    Ph: 414-649-5717

    Milwaukee

    Froedtert Hospital and Medical College of Wisconsin

    William H Bradley
    Ph: 414-805-4380

    Medical Consultants, Limited

    Robert L. Coleman
    Ph: 713-792-3245
    Email: rcoleman@mdanderson.org

    Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center

    Ali Mahdavi
    Ph: 414-649-5717

    New Richmond

    Cancer Center of Western Wisconsin

    Matthew P Boente
    Ph: 952-993-1517
    Email: MMCCOP@parknicollet.com

    Oconto Falls

    Green Bay Oncology, Limited - Oconto Falls

    Jonathan E Tammela
    Ph: 920-433-8889

    Oshkosh

    Vince Lombardi Cancer Clinic - Oshkosh

    Ali Mahdavi
    Ph: 414-649-5717

    Sheboygan

    Vince Lombardi Cancer Clinic - Sheboygan

    Ali Mahdavi
    Ph: 414-649-5717

    Sturgeon Bay

    Green Bay Oncology, Limited - Sturgeon Bay

    Jonathan E Tammela
    Ph: 920-433-8889

    Summit

    Aurora Medical Center

    Ali Mahdavi
    Ph: 414-649-5717

    Two Rivers

    Vince Lombardi Cancer Clinic - Two Rivers

    Ali Mahdavi
    Ph: 414-649-5717

    Wyoming
    Cheyenne

    Cheyenne Regional Medical Center

    Keren Sturtz
    Ph: 888-785-6789

    Japan

    Hiroshima City

    Hiroshima University Hospital

    Eiji Hirata
    Ph: 82-424-6042

    Kagoshima City, Kagoshima

    Kagoshima City Hospital

    Masayuki Hatae
    Ph: 011 81 099 224 2101

    Matsuyama

    Shikoku Cancer Center

    Takayoshi Nogawa
    Ph: 089-999-1172

    Osaka, Osaka

    Kinki University School of Medicine

    Masaki Mandai
    Ph: 072-366-0221

    Saitama

    Saitama Medical University International Medical Center

    Keiichi Fujiwara
    Ph: 81-49-276-2028

    Tokyo

    National Cancer Center Hospital

    Yasuhiro Fujiwara
    Ph: 81-3-3542-2511
    Email: www-admin@ncc.go.jp

    Tottori

    Tottori University Hospital

    Hiroaki Itamochi
    Ph: 0857-31-5007

    Aoba-ku
    Sendai

    Tohoku University Graduate School of Medicine

    Nobuo Yaegashi
    Email: med-som@bureau.tohoku.ac.jp

    Hiroshima
    Kure

    National Hospital Organization - Medical Center of Kure

    Kazuhiro Takehara
    Ph: 089-999-1172

    Hokkaido
    Sapporo

    Hokkaido University Hospital

    Noriaki Sakuragi
    Email: hassi@med.hokudai.ac.jp

    Iwate
    Morioka

    Iwate Medical University Hospital

    Toru Sugiyama
    Ph: 019-651-5111

    Niigata
    Niigata City

    Niigata University Medical and Dental Hospital

    Takayuki Enomoto
    Ph: 81-025-223-6161

    Republic of Korea

    Seoul

    Asan Medical Center - University of Ulsan College of Medicine

    Young-Tak Kim
    Email: irbksh@amc.seoul.kr

    Gangnam Severance Hospital

    Jae-Hoon Kim
    Email: clinical.trial@bms.com

    Korea Cancer Center Hospital

    Moon-Hong Kim
    Ph: 011-82-02-9702-114

    Seoul National University Hospital

    Jae W Kim
    Ph: 011-82-760-2384

    Suwon

    Ajou University Hospital

    Hee-Sug Ryu
    Ph: 031 219-4311~2

    Daegu
    Jung-Ku

    Dongsan Medical Center of Keimyung University

    Soon-Do Cha
    Email: ho@dsmc.or.kr

    Gyeonggi-do
    Goyang-si

    National Cancer Center - Korea

    Sang Y Park
    Ph: 011-82-760-2384

    KOREA
    Seoul

    Samsung Medical Center

    Duk-Soo Bae
    Ph: 011-82-1599-3114

    Kyeonggi-do
    Seongnam City

    Seoul National University Bundang Hospital

    Yong Beom Kim
    Ph: 011-82-760-2384

    Link to the current ClinicalTrials.gov record.
    NLM Identifier NCT00565851
    ClinicalTrials.gov processed this data on May 26, 2015

    Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.